122 related articles for article (PubMed ID: 7844604)
1. High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer.
Smith IE; Walsh G; Jones A; Prendiville J; Johnston S; Gusterson B; Ramage F; Robertshaw H; Sacks N; Ebbs S
J Clin Oncol; 1995 Feb; 13(2):424-9. PubMed ID: 7844604
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of continuous infusion fluorouracil with epirubicin and cisplatin in patients with metastatic and locally advanced breast cancer: an active new regimen.
Jones AL; Smith IE; O'Brien ME; Talbot D; Walsh G; Ramage F; Robertshaw H; Ashley S
J Clin Oncol; 1994 Jun; 12(6):1259-65. PubMed ID: 8201387
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of continuous infusional 5-fluorouracil with epirubicin and carboplatin (instead of cisplatin) in patients with metastatic/locally advanced breast cancer (infusional ECarboF): a very active and well-tolerated outpatient regimen.
Bonnefoi H; Smith IE; O'Brien ME; Seymour MT; Powles TJ; Allum WH; Ebbs S; Baum M
Br J Cancer; 1996 Feb; 73(3):391-6. PubMed ID: 8562348
[TBL] [Abstract][Full Text] [Related]
4. Primary medical (neo-adjuvant) chemotherapy for operable breast cancer.
Smith IE; Jones AL; O'Brien ME; McKinna JA; Sacks N; Baum M
Eur J Cancer; 1993; 29A(12):1796-9. PubMed ID: 8398318
[TBL] [Abstract][Full Text] [Related]
5. A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neo-adjuvant treatment of early breast cancer: 5 year results of the TOPIC trial.
Smith IE; A'Hern RP; Coombes GA; Howell A; Ebbs SR; Hickish TF; O'Brien ME; Mansi JL; Wilson CB; Robinson AC; Murray PA; Price CG; Perren TJ; Laing RW; Bliss JM;
Ann Oncol; 2004 May; 15(5):751-8. PubMed ID: 15111342
[TBL] [Abstract][Full Text] [Related]
6. Randomized phase II trial of infusional fluorouracil, epirubicin, and cyclophosphamide versus infusional fluorouracil, epirubicin, and cisplatin in patients with advanced breast cancer.
Eisen T; Smith IE; Johnston S; Ellis PA; Prendiville J; Seymour MT; Walsh G; Ashley S
J Clin Oncol; 1998 Apr; 16(4):1350-7. PubMed ID: 9552036
[TBL] [Abstract][Full Text] [Related]
7. Epirubicin, cisplatin, and prolonged or brief infusional 5-fluorouracil in the treatment of carcinoma of unknown primary site.
Karapetis CS; Yip D; Virik K; Strickland A; Ryder K; Cowling M; Harper PG
Med Oncol; 2001; 18(1):23-32. PubMed ID: 11778966
[TBL] [Abstract][Full Text] [Related]
8. Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features.
Balduzzi A; Montagna E; Bagnardi V; Torrisi R; Bertolini F; Mancuso P; Scarano E; Viale G; Veronesi P; Cardillo A; Orlando L; Goldhirsch A; Colleoni M
Anticancer Drugs; 2009 Mar; 20(3):197-203. PubMed ID: 19182679
[TBL] [Abstract][Full Text] [Related]
9. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
Klaassen U; Wilke H; Seeber S
Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
[TBL] [Abstract][Full Text] [Related]
10. Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial.
Del Mastro L; De Placido S; Bruzzi P; De Laurentiis M; Boni C; Cavazzini G; Durando A; Turletti A; Nisticò C; Valle E; Garrone O; Puglisi F; Montemurro F; Barni S; Ardizzoni A; Gamucci T; Colantuoni G; Giuliano M; Gravina A; Papaldo P; Bighin C; Bisagni G; Forestieri V; Cognetti F;
Lancet; 2015 May; 385(9980):1863-72. PubMed ID: 25740286
[TBL] [Abstract][Full Text] [Related]
11. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group.
Coombes RC; Bliss JM; Wils J; Morvan F; Espié M; Amadori D; Gambrosier P; Richards M; Aapro M; Villar-Grimalt A; McArdle C; Pérez-López FR; Vassilopoulos P; Ferreira EP; Chilvers CE; Coombes G; Woods EM; Marty M
J Clin Oncol; 1996 Jan; 14(1):35-45. PubMed ID: 8558217
[TBL] [Abstract][Full Text] [Related]
13. Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for advanced gastric carcinoma.
Cho EK; Lee WK; Lim DY; Bang SM; Park DK; Park YH; Kwon OS; Choi DJ; Shin DB; Lee JH; Lee TH
J Korean Med Sci; 2002 Jun; 17(3):348-52. PubMed ID: 12068138
[TBL] [Abstract][Full Text] [Related]
14. [Early stage breast cancer: is exclusive radiotherapy an option for early breast cancers with complete clinical response after neoadjuvant chemotherapy?].
Daveau C; Savignoni A; Abrous-Anane S; Pierga JY; Reyal F; Gautier C; Kirova YM; Dendale R; Campana F; Fourquet A; Bollet MA
Cancer Radiother; 2011 Apr; 15(2):106-14. PubMed ID: 21084207
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of epirubicin, cisplatin and capecitabine as neoadjuvant chemotherapy in locally advanced or inflammatory breast cancer.
Villman K; Ohd JF; Lidbrink E; Malmberg L; Lindh B; Blomqvist C; Nordgren H; Bergh J; Bergström D; Ahlgren J
Eur J Cancer; 2007 May; 43(7):1153-60. PubMed ID: 17398088
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-naïve patients with locally advanced or metastatic breast carcinoma.
Hsu C; Huang CS; Chao TY; Lu YS; Bu CF; Chen MM; Chang KJ; Cheng AL
Cancer; 2002 Nov; 95(10):2044-50. PubMed ID: 12412156
[TBL] [Abstract][Full Text] [Related]
17. Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel.
Torrisi R; Balduzzi A; Ghisini R; Rocca A; Bottiglieri L; Giovanardi F; Veronesi P; Luini A; Orlando L; Viale G; Goldhirsch A; Colleoni M
Cancer Chemother Pharmacol; 2008 Sep; 62(4):667-72. PubMed ID: 18064460
[TBL] [Abstract][Full Text] [Related]
18. Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for esophagogastric adenocarcinoma: response, toxicity, quality of life, and survival.
Bamias A; Hill ME; Cunningham D; Norman AR; Ahmed FY; Webb A; Watson M; Hill AS; Nicolson MC; O'Brien ME; Evans TC; Nicolson V
Cancer; 1996 May; 77(10):1978-85. PubMed ID: 8640659
[TBL] [Abstract][Full Text] [Related]
19. High pathologic complete response in HER 2-positive locally advanced breast cancer after primary systemic chemotherapy with weekly docetaxel and epirubicin.
Chen SC; Chang HK; Lin YC; Hsueh S; Cheung YC; Leung WM; Tsai CS; Lo YF; Tsai HP; Shen SC; Chen MF
Jpn J Clin Oncol; 2008 Feb; 38(2):99-105. PubMed ID: 18270380
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of epirubicin, cisplatin, oral uracil and tegafur, and leucovorin in patients with advanced gastric carcinoma.
Jeen YT; Yoon SY; Shin SW; Kim BS; Mok YJ; Kim CS; Hyun JH; Kim JS; Kim YH
Cancer; 2001 Jun; 91(12):2288-93. PubMed ID: 11413517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
